CG
RLMD icon

Cutler Group’s Relmada Therapeutics RLMD Stock Holding History

Cutler Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,600
Closed -$64K – 5077
2022
Q3 		$64K Sell
4,600
-2,100
-31% -$58.2K ﹤0.01% 1726
2022
Q2 		$9K Sell
6,700
-8,700
-56% -$190K ﹤0.01% 3298
2022
Q1 		$122K Buy
+15,400
New +$318K 0.01% 1556
2021
Q3 		– Sell
-4,400
Closed -$16K – 6256
2021
Q2 		$16K Buy
+4,400
New +$153K ﹤0.01% 3507
2021
Q1 		– Sell
-2,000
Closed -$1K – 6171
2020
Q4 		$1K Hold
2,000
– – ﹤0.01% 4524
2020
Q3 		$6K Sell
2,000
-6,100
-75% -$236K ﹤0.01% 3386
2020
Q2 		$30K Buy
8,100
+5,400
+200% +$228K ﹤0.01% 2104
2020
Q1 		$4K Buy
2,700
+600
+29% +$24.2K ﹤0.01% 3218
2019
Q4 		$17K Buy
+2,100
New +$63.8K ﹤0.01% 2314

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RLMD Position: Q1 2024 in Review

Cutler Group reduced its Relmada Therapeutics (RLMD) stake by 3.2% in Q1 2024, selling an estimated $1.45K and leaving 9,000 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #756.

Cutler Group first reported a position in RLMD in Q1 2020 and has held it in 16 quarters since. The position peaked at $388K in Q3 2022. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • Cutler Group held 9,000 shares of Relmada Therapeutics worth $41K as of Q1 2024.
  • Cutler Group sold 300 Relmada Therapeutics shares in Q1 2024, an estimated $1.45K.
  • Relmada Therapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #756 holding.
  • Cutler Group first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Cutler Group's Relmada Therapeutics position peaked at $388K in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.